Medical news today: Tuesday, October 27, 2026

Nigeria's Ebola patient is flown to Switzerland, FDA clears an earlier prostate cancer combination, and Bangladesh's measles toll passes 1,200

1. 01
   27 Oct, 07:07 IST

   FDA approves Pfizer's Talzenna plus Xtandi earlier in advanced prostate cancer

   Source: FDA

   On 26 October the US FDA approved Pfizer's talazoparib (Talzenna, a pill that blocks the PARP DNA-repair enzyme) with enzalutamide (a hormone-blocking drug) for adults with metastatic prostate cancer that is still sensitive to, or has not yet been treated with, hormone-pathway drugs and that carries certain DNA-repair (HRR) gene mutations found by an FDA-authorised test. The approval rests on the TALAPRO-3 trial, which randomised 599 patients to enzalutamide plus talazoparib or placebo, alongside standard hormone therapy.

   Why it mattersMen whose prostate cancer has spread and carries these gene changes can now get this two-drug combination at an earlier stage of the disease in the US, which makes genetic testing of the tumour more important for choosing treatment. More on Approvals & regulatory →
2. 02
   27 Oct, 07:07 IST

   India's drug regulator flags falsified batch of Defitelio, a drug for a rare liver complication

   Source: CDSCO (India)

   India's Central Drugs Standard Control Organisation (CDSCO) posted a public notice on 26 October about a WHO alert on a falsified batch of DEFITELIO (defibrotide) 80 mg/ml concentrate for infusion, batch 24GC01A, expiry 04/2027, identified in India. The label names Patheon in Italy as manufacturer and Gentium S.r.l. as marketing authorisation holder.

   Why it mattersDefibrotide is a hospital drug used for a rare, life-threatening blockage of liver blood vessels after stem cell transplants, so a fake batch could leave very sick patients untreated; hospitals and families should only use medicines bought through authorised suppliers. More on Approvals & regulatory →
3. 03
   27 Oct, 07:07 IST

   India's CDSCO issues notice on misleading claims for FatX cosmetic solution

   Source: CDSCO (India)

   India's Central Drugs Standard Control Organisation posted a public notice on 26 October titled 'Misleading or false claims of the product FatX solution', a cosmetic registered (registration RC/COS-003300) by the firm Tekno Midas Aesthetics. The listing does not summarise which claims were found misleading.

   Why it mattersA cosmetic registration does not mean a product is proven to do what its marketing says, and India's regulator is signalling it will act against beauty products sold with claims they cannot back up. More on Approvals & regulatory →
4. Advertise here · reach a global health-curious audience →
5. 04
   27 Oct, 05:30 IST

   Southern Trust plans to move Daisy Hill maternity care to Craigavon

   Source: BBC Health

   BBC Health reports: The Southern Health Trust plans to temporarily transfer inpatient maternity services from Daisy Hill to Craigavon.

   Why it mattersThe Southern Health Trust plans to temporarily transfer inpatient maternity services from Daisy Hill to Craigavon, so women in that area would give birth away from their local hospital.
6. 05
   27 Oct, 03:24 IST

   Bon Secours Mercy Health strikes $5.7 billion surgery center deal (STAT+, paywall)

   Source: STAT

   STAT reports: The deal would make the Catholic system one of the largest operators of outpatient surgery centers.

   Why it mattersThe deal would make the Catholic nonprofit system one of the largest operators of outpatient surgery centers. More on Pharma industry →
7. 06
   27 Oct, 02:46 IST

   HHS relaxes security and transparency rules for hospital record software (STAT+, paywall)

   Source: STAT

   STAT reports: The Trump administration removed several security, privacy and transparency requirements for vendors of EHR software.

   Why it mattersThe administration removed several security, privacy and transparency requirements for vendors of electronic health record software that hospitals use.
8. Advertise here · reach a global health-curious audience →
9. 07
   27 Oct, 02:30 IST

   Obesity in young adults linked to higher risk of early cancers in 6.3-million-person Korean study

   Source: MedPage Today

   A South Korean study of 6.3 million adults aged 20 to 39, published in Annals of Internal Medicine, found obesity in young adulthood was associated with more early-onset cancers, a risk that persisted into middle age. The 10-year cancer rate rose from 1.84% in normal-weight people to 2.62% in the heaviest group; risk was higher in men and with belly fat, and was highest for thyroid, endometrial and ovarian cancers. The authors note the absolute differences were modest and the study is observational.

   Why it mattersCancers in people under 50 are rising worldwide, and this adds evidence that weight in early adulthood may matter, although the study shows a link rather than proof that obesity caused the cancers. More on Oncology →
10. 08
    27 Oct, 02:30 IST

    AI note-taking scribe saves doctors a few minutes but doesn't boost productivity, study finds

    Source: MedPage Today

    At Beth Israel Lahey Health, a 14-hospital US system, clinicians using the Heidi AI ambient scribe (software that listens to visits and drafts notes) cut median note-writing time from 21 to 18.6 minutes, and notes got longer, but same-day note completion and clinical productivity did not change, according to a study in Annals of Internal Medicine. An editorial warned that the long-term effects of AI-generated content in medical records, including possible errors, are unknown.

    Why it mattersMore doctors worldwide are using AI tools that listen in on appointments; this shows the time savings are modest so far, and raises questions about the accuracy of what ends up in patients' records. More on Pharma industry →
11. 09
    27 Oct, 02:30 IST

    Hair-loss product sales jump as GLP-1 weight-loss drug use grows, Cosmetics Business reports

    Source: Cosmetics Business

    Cosmetics Business reports that Worldpanel by Numerator estimates UK sales of hair-loss products grew 32% in the year to the end of August, with a likely link to rising use of GLP-1 drugs such as Ozempic, Mounjaro and Wegovy, used by 6.3% of households in Great Britain this year. It cites a BMJ study linking GLP-1 drugs to a higher, though low absolute, risk of hair loss.

    Why it mattersHair shedding is a known possible side effect of rapid weight loss on these drugs, and brands are rushing in with products, so it is worth discussing hair changes with a doctor rather than relying on marketing claims. More on Obesity & metabolic →
12. Advertise here · reach a global health-curious audience →
13. 10
    27 Oct, 02:17 IST

    GLP-1 weight-loss drugs tied to fewer MS relapses in large US real-world study

    Source: MedPage Today

    Among 339,092 US people with multiple sclerosis (MS), the 14,300 who used GLP-1 drugs (the diabetes and obesity medicines such as semaglutide) had fewer steroid-treated relapses (1.85% vs 4.84%) and less optic neuritis (eye-nerve inflammation) over 12 years than matched non-users, researchers reported at the ECTRIMS-ACTRIMS meeting. The researchers say prospective studies are needed to know whether the drugs truly protect against MS.

    Why it mattersMS affects millions worldwide, and if GLP-1 drugs really calm nerve inflammation it could open a new treatment angle, but this kind of records study cannot prove cause and effect. More on Infectious disease →
14. 11
    27 Oct, 00:55 IST

    Supplement industry urges NIH to keep its Office of Dietary Supplements independent

    Source: NutraIngredients

    Four US supplement trade groups (AHPA, CHPA, CRN and UNPA) filed joint comments asking the National Institutes of Health to reconsider a proposal to move its Office of Dietary Supplements (ODS) under the Office of Nutrition Research, warning it could weaken the office's congressional mandate and scientific reach. Public comment on the proposal is open until 28 October.

    Why it mattersThe ODS runs widely used, free fact sheets and research on vitamins and supplements, so where it sits inside NIH could affect how much independent science consumers have to judge supplement claims. More on Nutraceuticals & supplements →
15. 12
    27 Oct, 00:55 IST

    Surgery Partners shares surge over 48% on Bon Secours buyout reports; Xencor jumps 17% on kidney cancer data

    Source: RTTNews

    RTTNews reports Surgery Partners (SGRY) shares surged over 48% on Monday after reports that nonprofit Bon Secours Mercy Health was in late-stage talks to buy a majority stake in the outpatient surgery chain in a deal valued at about $6 billion including debt. Xencor (XNCR) rose about 17% on updated Phase 1 ESMO data for XmAb819 in advanced kidney cancer, and Oruka Therapeutics (ORKA) gained over 12% after Phase 2b psoriasis results in which 61% of patients on the 600 mg dose reached complete skin clearance.

    Why it mattersBig moves like these show investors betting on outpatient surgery consolidation and on new immune-based treatments for kidney cancer and psoriasis, which could reach patients if later trials succeed. Not investment advice. More on Oncology →

    Market news · Not investment advice

16. Advertise here · reach a global health-curious audience →
17. 13
    27 Oct, 00:47 IST

    Obesity drugmaker Corxel to go public via SPAC with $300 million to push its GLP-1 pill

    Source: BioPharma Dive

    Corxel Pharmaceuticals will go public by merging with the blank-cheque company (SPAC) Amanat Acquisition Corp., with a concurrent $300 million private investment to take CX11, a GLP-1 weight-loss pill licensed from China's Vincentage Pharma, into late-stage testing. Corxel said in June that CX11 helped people in a US Phase 2 trial lose an average of up to 11.5% of body weight after 36 weeks; an international Phase 3 could start as soon as early 2027.

    Why it mattersInvestors are putting more money into weight-loss pills as an alternative to injections, which could eventually mean more choice and price competition for people who need them. Not investment advice. More on Infectious disease →

    Market news · Not investment advice

18. 14
    27 Oct, 00:45 IST

    Ebola patient flown from Nigeria to Switzerland as a nurse is killed in DR Congo

    Source: CBC News (AP)

    Nigeria's first Ebola patient in this outbreak, a Ugandan-born Swiss citizen, was medically evacuated from Abuja to Switzerland on Monday while Nigerian authorities monitor 52 of her contacts; officials are still working out how she was infected. In DR Congo, a nurse was killed and another health worker badly injured in an attack while responding to an Ebola alert in Tshopo province, and the Health Ministry's latest data show more than 9,800 cases and 4,700 deaths since May. Uganda now requires citizens returning from DR Congo to quarantine for 21 days, and Kenya released its first 20 contacts from quarantine after 21 days without symptoms.

    Why it mattersThe Bundibugyo Ebola outbreak (a strain with no approved vaccine) is now touching four countries, and attacks on health workers fuelled by rumours make it harder to stop the spread, while contact tracing in Kenya and Nigeria shows how imported cases can be contained. More on Approvals & regulatory →
19. 15
    26 Oct, 19:18 IST

    Bangladesh measles deaths reach 1,233 as six more children die in 24 hours

    Source: The Daily Star (Bangladesh)

    Six more children died of measles-like symptoms in Bangladesh in the 24 hours to 8am on 26 October, taking confirmed and suspected measles deaths to 1,233 since 15 March, according to the Directorate General of Health Services (DGHS). Another 1,388 suspected and 78 confirmed cases were logged that day; suspected cases now total 222,552 and lab-confirmed infections 23,478.

    Why it mattersMeasles is highly contagious and can kill young children, but it is preventable with two doses of vaccine; an outbreak of this size is a reminder of what happens when childhood vaccination gaps open up. More on Drug & device safety →
20. Advertise here · reach a global health-curious audience →
21. 16
    26 Oct, 18:54 IST

    Amgen's Imdelltra with AstraZeneca's Imfinzi cuts risk of death by 58% in small cell lung cancer, study shows

    Source: The Hindu (Reuters)

    Amgen's Imdelltra (tarlatamab, an antibody that steers immune cells to cancer cells) added to AstraZeneca's immunotherapy Imfinzi reduced the risk of death by 58% versus Imfinzi alone in extensive-stage small cell lung cancer that had not worsened after first chemotherapy, according to a 563-patient trial presented at ESMO in Madrid and published in NEJM. Patients on both drugs lived a median of 21.1 months versus 12.7 months; Reuters notes Imdelltra's US list price is about $30,000 per cycle.

    Why it mattersSmall cell lung cancer is one of the most aggressive cancers with few good options, so a combination that lengthens survival when given earlier could change standard care, although the high price may limit who can get it. More on Drug & device safety →